Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;18(2):285-96.
doi: 10.1007/s10895-007-0268-z. Epub 2007 Nov 6.

Determination of enantiomeric compositions of analytes using novel fluorescent chiral molecular micelles and steady state fluorescence measurements

Affiliations

Determination of enantiomeric compositions of analytes using novel fluorescent chiral molecular micelles and steady state fluorescence measurements

Alicia A Williams et al. J Fluoresc. 2008 Mar.

Abstract

Novel fluorescent chiral molecular micelles (FCMMs) were synthesized, characterized, and employed as chiral selectors for enantiomeric recognition of non-fluorescent chiral molecules using steady state fluorescence spectroscopy. The sensitivity of the fluorescence technique allowed for investigation of low concentrations of chiral selector (3.0 x 10(-5) M) and analyte (5.0 x 10(-6) M) to be used in these studies. The chiral interactions of glucose, tartaric acid, and serine in the presence of FCMMs poly(sodium N-undecanoyl-L-tryptophanate) [poly-L-SUW], poly(sodium N-undecanoyl-L-tyrosinate) [poly-L-SUY], and poly(sodium N-undecanoyl-L-phenylalininate) [poly-SUF] were based on diastereomeric complex formation. Poly-L-SUW had a significant fluorescence emission spectral difference as compared to poly-L-SUY and poly-L-SUF for the enantiomeric recognition of glucose, tartaric acid, and serine. Studies with the hydrophobic molecule alpha-pinene suggested that poly-L-SUY and poly-L-SUF had better chiral discrimination ability for hydrophobic analytes as compared to hydrophilic analytes. Partial-least-squares regression modeling (PLS-1) was used to correlate changes in the fluorescence emission spectra of poly-L-SUW due to varying enantiomeric compositions of glucose, tartaric acid, and serine for a set of calibration samples. Validation of the calibration regression models was determined by use of a set of independently prepared samples of the same concentration of chiral selector and analyte with varying enantiomeric composition. Prediction ability was evaluated by use of the root-mean-square percent relative error (RMS%RE) and was found to range from 2.04 to 4.06%.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Molecular structures of a poly-L-SUW; b poly-L-SUY; c poly-L-SUF; d glucose; e tartaric acid; f serine; g α-pinene
Fig. 2
Fig. 2
Circular dichroism spectra of a poly-D-SUW and poly-L-SUW; b poly-D-SUY and poly-L-SUY; c poly-D-SUF and poly-L-SUF
Fig. 3
Fig. 3
Fluorescence emission spectra and mean-centered spectral plots of 3.0×10−5 M a poly-L-SUW [λex =280 nm]; b poly-L-SUY [λex= 280 nm]; c poly-L-SUF [λex =260 nm] in the presence of 5.0×10−6 M enantiomers of 1 Glucose; 2 Tartaric acid; 3 Serine
Fig. 4
Fig. 4
Fluorescence emission spectra and mean-centered spectral plots of 3.0×10−5 M a Poly-L-SUY [λex =280 nm]; b Poly-L-SUF [λex= 260 nm] in the presence of 5.0×10−6 M enantiomers of α-pinene
Fig. 5
Fig. 5
Fluorescence emission spectra and mean-centered spectral plots of 3.0×10−5 M Poly-L-SUW [λex=280 nm] in the presence of 5.0×10−6 M enantiomers of a Glucose; b Tartaric acid; c Serine with varied mole fractions: (1) 1.0 D; (2) 0.9 D; (3) 0.8 D; (4) 0.7 D; (5) 0.6 D; (6) 0.5 D; (7) 0.4 D; (8) 0.3 D; (9) 0.2 D; (10) 0.1 D; (11) 0.0 D
Scheme 1
Scheme 1
Synthetic scheme for FCMMs

Similar articles

References

    1. Hacksell U, Ahlenius S. Chirality in drug research design. Trends Biotechnol. 1993;11(3):73–74. - PubMed
    1. Witte DT. Development and registration of chiral drugs. Pharm World Sci. 1993;15(1):10–16. - PubMed
    1. Subramanian G. Chiral separation techniques: a practical approach. 2. Wiley-VCH; Weinheim: 2001.
    1. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov. 2002;1(10):753–768. - PubMed
    1. US Food and Drug Administration. Development of new stereoisomeric drugs [policy statement] 1992;22:249.

Publication types

MeSH terms